In a recent press release, immuno-oncology and biopharmaceutical company GT Biopharma, Inc. ("GT") shared the release of new data and results from the Phase 1/2 GTB-3550 TriKE clinical trial. Through…
Cancer Network recently reported that Jazz Pharmaceuticals’ Vyxeos was approved by the FDA to treat therapy-related pediatric patients one year or older who were newly diagnosed with acute myeloid…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
According to BioSpace, Kronos Bio will continue with its plans for a Phase 3 trial of entospletinib after a positive meeting with the FDA. One of the meeting's focuses was…
As reported in NewsWise, as rare diseases get their time under the microscope, growing evidence uncovers medical distinctions. New lines are drawn, delineating new disorders to be defined and classified.…
The first patient has been dosed in a Phase 1 clinical trial, which is exploring Curis Inc.'s CA-4948 in conjunction with ibrutinib for hematologic malignancies. Examples of hematologic malignancies include…
In an early February press release, pharmaceutical company Astellas Pharma Inc. ("Astellas") shared that XOSPATA (gilteritinib) was given conditional approval in China for the treatment of patients with FLT3-mutated…
Poly (ADP-Ribose) polymerase inhibitors (PARP inhibitors) are used to treat neoplasms. They are frequently used as a therapy for ovarian cancer. A recent study has attempted to detect the possibility…
Dr. Andrew Brunner, an oncologist at Massachusetts Cancer Center was recently interviewed by Targeted Oncology. The discussion centered around a phase 1b clinical trial (NCT03066648) investigating sabatolimab together with hypomethylating…
While novel treatments have been rapidly emerging onto the drug scene, new treatment options for pancreatic cancer have fallen behind. But now, according to OncLive’s interview with Dr. P.A. Philip,…
Kura Oncology, a San Diego biopharmaceutical company, was recently featured in a Globe Newswire article, announcing its first-in-human dose escalation of KO-539 being evaluated in the Komet-001 trial (NCT04067336). The…
In early December 2020, biopharmaceutical company Gilead Sciences, Inc. ("Gilead") shared updated results from a Phase 1b clinical trial evaluating magrolimab for patients with treatment-naïve acute myeloid leukemia (AML). Generally,…
Xencor, a biopharmaceutical company that focuses on curating treatments for cancers and autoimmune conditions, has recently released data on vibecotamab. This acute myeloid leukemia treatment was included in a Phase…
According to a story from PR Newswire, the pharmaceutical and diagnostics company The Menarini Group recently announced that its drug tagraxofsup (marketed as Elzonris) has a received a positive opinion…
Recently, biopharmaceutical company Nkarta announced the dosing of the first patient in its Phase 1 clinical trial. Within the trial, researchers will evaluate and analyze the company's investigational therapy,…
Astellas Pharma, headquartered in Northbrook, Illinois presents its Be R/Ready program to promote patient-physician communication as well as other valuable and informative resources. Their program centers around patients with relapsed…
According to a story from fiercepharma.com, the US Food and Drug Administration (FDA) was willing to approve the drug Tibsovo as a treatment for acute myeloid leukemia (AML) following encouraging…
Blood cancer treatment is undergoing a transformation, according to a recent study in Nature Medicine. In this regard, the Leukemia & Lymphoma Society (LLS) recently published its own account featuring…
A new study has uncovered that using a hypomethylating agent in combination with a BCL2 inhibitor called Venetoclax may be advantageous as a therapeutic option for individuals with acute myeloid…
According to a story from BioSpace, the biotechnology company Ascentage Pharma announced that two of its investigational treatments have recently received Orphan Drug designation from the US Food and Drug…
Immune-One Therapeutics has just announced that they have dosed their first acute myeloid leukemia (AML) patient in their Phase 1 trial investigating IO-202. This therapy is an immune inhibitory receptor that works…
Jazz Pharmaceuticals has launched an educational program called Find the Right Fit, which aims to spread awareness and help patients with myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML).…
Recently, the MDS Foundation announced that two TP53 gene mutations result in worse patient outcomes in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). According to their international and multi center study,…
Earlier this week, the FDA approved oral azacitidine (Onureg) for patients with acute myeloid leukemia (AML). According to the ASCO Post, Onureg continuously treats adult patients who previously achieved remission.…
Recently, biopharmaceutical company BerGenBio ASA ("BerGenBio") announced that their drug candidate bemcentinib reached its primary efficacy endpoint in a Phase 2 clinical trial. The drug is designed to treat patients…
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
